Paroxysmal nocturnal hemoglobinuria

Search Trials
Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Active, not recruiting
Last Changed:
Feb 18, 2019
First Changed:
Nov 17, 2015
Disease(s):
Paroxysmal Nocturnal Hemoglobinuria
Intervention(s):
Ravulizumab
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Active, not recruiting
Last Changed:
May 16, 2019
First Changed:
Oct 27, 2016
Disease(s):
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention(s):
RavulizumabEculizumab
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status:
Active, not recruiting
Last Changed:
May 16, 2019
First Changed:
Feb 16, 2017
Disease(s):
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention(s):
RavulizumabEculizumab
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Recruiting
Last Changed:
Jun 13, 2019
First Changed:
May 13, 2019
Disease(s):
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention(s):
REGN3918
A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria
Status:
Recruiting
Last Changed:
Sep 9, 2019
First Changed:
Aug 15, 2019
Disease(s):
Paroxysmal Nocturnal Hemoglobinuria
Intervention(s):
SB12 (proposed eculizumab biosimilar)Soliris (eculizumab)

Connect. Empower. Inspire.